Volume 5, Issue 4 (Nov 2017)                   Res Mol Med (RMM) 2017, 5(4): 1-11 | Back to browse issues page

XML Print

1- Razi Herbal Medicines Research Center, Lorestan University of Medical Sciences, Khorramabad, Iran
2- Department of Laboratory Sciences, Torbat Heydariyeh University of Medical Sciences, Torbat Heydariyeh, Iran
3- Department of Laboratory Sciences, Sirjan Faculty of Medical Sciences, Sirjan, Iran
4- Lorestan Provincial Veterinary Service, Khorramabad, Iran
5- Department of Parasitology and Mycology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran , pestechian@med.mui.ac.ir
6- Department of Physiology and Pharmacology, Immunogenetics Research Center, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran
Abstract:   (2258 Views)
Toxoplasma gondii is well- known as a common parasite with high proliferative activity in the nucleated cells. This parasite has infected nearly one third of the people worldwide. Infection can result in chorioretinitis in immunocompetent hosts, encephalitis in HIV/AIDS positive patients and abortion and neonatal loss in congenital toxoplasmosis. Development of vaccines for toxoplasmosis infection is very important for decreasing infection transmission routes of the disease in various host species in the world. Live attenuated vaccines are closest to a natural infection; therefore, they are good rescuers of the immune system and often create lifelong immunity with only one or two doses. In this study, the researchers reviewed the current status in the development of live attenuated vaccines on Toxoplasma infection.

Full-Text [PDF 342 kb]   (766 Downloads)    
Type of Study: review | Subject: Biotechnology
Received: 2018/05/6 | Accepted: 2018/07/15 | Published: 2017/11/15